113 related articles for article (PubMed ID: 23611272)
1. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy.
Bickenbach K; Wilcox R; Veerapong J; Kindler HL; Posner MC; Noffsinger A; Roggin KK
J Gastrointest Surg; 2007 Jun; 11(6):758-66. PubMed ID: 17417711
[TBL] [Abstract][Full Text] [Related]
2. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.
Revheim ME; Kristian A; Malinen E; Bruland ØS; Berner JM; Holm R; Joensuu H; Seierstad T
Acta Oncol; 2013 May; 52(4):776-82. PubMed ID: 23480638
[TBL] [Abstract][Full Text] [Related]
3. Emergence of secondary resistance to imatinib in recurrent gastric GIST.
Jayanthi NV
J Gastrointest Surg; 2010 Dec; 14(12):2018-9; author reply 2020. PubMed ID: 20714935
[No Abstract] [Full Text] [Related]
4. Giant GIST of the small intestine in a young man.
Atmatzidis S; Chatzimavroudis G; Ananiadis A; Kapoulas S; Atmatzidis K
J Gastrointest Surg; 2013 Aug; 17(8):1536-7. PubMed ID: 23797887
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.
Jiang J; Jin MS; Suo J; Wang YP; He L; Cao XY
World J Gastroenterol; 2012 May; 18(20):2569-75. PubMed ID: 22654456
[TBL] [Abstract][Full Text] [Related]
6. The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.
DeCaprio JA; Duensing A
Curr Opin Oncol; 2014 Jul; 26(4):415-21. PubMed ID: 24840522
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.
Kang YK; Kim KM; Sohn T; Choi D; Kang HJ; Ryu MH; Kim WH; Yang HK;
J Korean Med Sci; 2010 Nov; 25(11):1543-52. PubMed ID: 21060741
[TBL] [Abstract][Full Text] [Related]
8. Recent advances for treatment of upper gastrointestinal malignancy.
Sestito M; Pratt H; Schmidt C; Thomay A
J Surg Oncol; 2024 Jan; 129(1):48-62. PubMed ID: 38010879
[TBL] [Abstract][Full Text] [Related]
9. Imatinib plasma levels in patients with gastrointestinal stromal tumour under routine clinical practice conditions.
Del Rosario García B; Morales Barrios JA; Jurado JC; Díaz RR; Viña Romero MM; Padrón IM; Nazco Casariego GJ; Nicolás FG
J Oncol Pharm Pract; 2023 Oct; 29(7):1613-1618. PubMed ID: 36482704
[TBL] [Abstract][Full Text] [Related]
10. Case of Imatinib Susceptibility to CYP3A4-Mediated Drug-Drug Interactions in a Patient With Gastrointestinal Stromal Tumor.
Fujimiya T; Sugita H; Kin M; Funakoshi H; Kubota Y; Tsunoda T
Am J Ther; 2024 Jan-Feb 01; 31(1):e66-e69. PubMed ID: 35792063
[No Abstract] [Full Text] [Related]
11. Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors.
Duensing S; Duensing A
Oncotarget; 2010 May; 1(1):6-8. PubMed ID: 21293050
[No Abstract] [Full Text] [Related]
12. Targeted therapy in sarcomas other than GIST tumors.
Sborov D; Chen JL
J Surg Oncol; 2015 Apr; 111(5):632-40. PubMed ID: 25330750
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic approaches for advanced gastrointestinal stromal tumors.
Somaiah N; von Mehren M
Hematol Oncol Clin North Am; 2009 Feb; 23(1):139-50, x. PubMed ID: 19248977
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the systemic treatment of gastrointestinal stromal tumors.
Jones RL; Golčić M
Cancer Biol Med; 2023 Oct; 20(10):701-5. PubMed ID: 37874125
[No Abstract] [Full Text] [Related]
15. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
16. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Shen L
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
[No Abstract] [Full Text] [Related]
17. [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
Chen LR
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):440-3. PubMed ID: 17845754
[No Abstract] [Full Text] [Related]
18. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
19. [Chinese consensus in diagnosis and treatment of gastrointestinal stromal tumor].
Chinese Diagnosis and Treatment Experts Group for Gastrointestinal Stromal Tumors
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):697-702. PubMed ID: 20078976
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
